CORV Correvio Pharma Corporation

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13A-16 or 15d-16 of

The Securities Exchange Act of 1934

 

For the month of June 2019

 

COMMISSION FILE Number. 000-29338

 

CORREVIO PHARMA CORP.

(Translation of registrant’s name into English)

 

1441 Creekside Drive, 6th floor

Vancouver, British Columbia, V6J 4S7, CANADA

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

 

Form 20-F ☐

Form 40-F ☒

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

  

 

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

Exhibit		Description
99.1		News Release dated June 18, 2019

  

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	CORREVIO PHARMA CORP.
	(Registrant)
Date: June 18, 2019	By:	/s/ Justin Renz
		Name: Justin Renz
		Title: President and Chief Financial Officer

 

 

Exhibit 99.1

 

 

Correvio Announces Voting Results

 

NASDAQ: CORV  TSX: CORV

VANCOUVER, June 18, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the results of voting at its 2019 Annual General Meeting of Shareholders held on June 18, 2019.

A total of 31,281,191 common shares were voted in connection with the meeting, representing approximately 78.39% of the issued and outstanding common shares of the company. Shareholders voted as follows:

Election of Directors

By resolution passed by ballot vote, the following seven nominees proposed by management were elected as directors of Correvio to hold office until the next annual meeting of Shareholders or until their successors are elected or appointed:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
Richard M. Glickman	10,612,281	56.76%	8,083,070	43.24%
W. James O'Shea	18,212,631	97.42%	482,720	2.58%
William L. Hunter	18,223,315	97.48%	472,036	2.52%
Mark H. Corrigan	18,169,795	97.19%	525,556	2.81%
Arthur H. Willms	18,222,565	97.47%	472,786	2.53%
Robert J. Meyer	18,222,560	97.47%	472,791	2.53%
Vanda de Cian	18,224,350	97.48%	471,001	2.52%

 

Appointment of Auditor

By resolution passed by show of hands, KMPG LLP, Chartered Professional Accountants, was appointed auditor of the company for the ensuing year.

About Correvio Pharma Corp.

Correvio Pharma Corp. is a specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba^™ (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera^®/Mabelio^® (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess^®™ (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat^® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, and Esmocard^® and Esmocard Lyo^® (esmolol hydrochloride), a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Correvio's pipeline of product candidates includes Trevyent^®, a drug device combination that is designed to deliver treprostinil, the world's leading treatment for pulmonary arterial hypertension.

Correvio is traded on the NASDAQ Capital Market (CORV) and the Toronto Stock Exchange (CORV). For more information, please visit our web site www.correvio.com.

Correvio^® and the Correvio Logo are the proprietary trademarks of Correvio Pharma Corp.
Aggrastat^® and Brinavess^®™ are trademarks owned by Correvio and its affiliates worldwide.
Xydalba^™ is a trademark of Allergan Pharmaceuticals International Limited, and used under license.
Zevtera^® and Mabelio^® are trademarks owned by Basilea Pharmaceutica International Ltd., and used under license.
Esmocard^® and Esmocard Lyo^® are trademarks owned by Orpha-Devel Handels und Vertriebs GmbH, and used under license.
Trevyent^® is a trademark of SteadyMed Ltd. and used under license.
All other trademarks are the property of their respective owners.

View original content:http://www.prnewswire.com/news-releases/correvio-announces-voting-results-300870893.html

SOURCE Correvio Pharma Corp

View original content: http://www.newswire.ca/en/releases/archive/June2019/18/c1312.html

%CIK: 0001036141

For further information: Justin Renz, President & CFO, Correvio Pharma Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@correvio.com; Argot Partners, Michelle Carroll/Claudia Styslinger, 212.600.1902, correvio@argotpartners.com

CO: Correvio Pharma Corp

CNW 19:10e 18-JUN-19

This regulatory filing also includes additional resources:
ex991.pdf